Identification of reproducible drug-resistance-related dysregulated genes in small-scale cancer cell line experiments

Researchers usually measure only a few technical replicates of two types of cell line, resistant or sensitive to a drug, and use a fold-change (FC) cut-off value to detect differentially expressed (DE) genes. However, the FC cut-off lacks statistical control and is biased towards the identification of genes with low expression levels in both cell lines. Here, viewing every pair of resistant-sensitive technical replicates as an experiment, we proposed an algorithm to identify DE genes by evaluating the reproducibility of the expression difference or FC between every two independent experiments without overlapping samples. Using four small datasets of cancer cell line resistant or sensitive to a drug, we demonstrated that this algorithm could efficiently capture reproducible DE genes significantly enriched in biological pathways relevant to the corresponding drugs, whereas many of them could not be found by the FC and other commonly used methods. Therefore, the proposed algorithm is an effective complement to current approaches for analysing small cancer cell line data.

[1]  J. Valcárcel,et al.  The spliceosome as a target of novel antitumour drugs , 2012, Nature Reviews Drug Discovery.

[2]  Robert Brown,et al.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.

[3]  X. Lin,et al.  P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. , 2001, Cancer research.

[4]  John Quackenbush Microarray data normalization and transformation , 2002, Nature Genetics.

[5]  G. Giaccone,et al.  Cathepsin B Mediates Caspase-Independent Cell Death Induced by Microtubule Stabilizing Agents in Non-Small Cell Lung Cancer Cells , 2004, Cancer Research.

[6]  Jing Zhu,et al.  GO-function: deriving biologically relevant functions from statistically significant functions , 2012, Briefings Bioinform..

[7]  J. Foekens,et al.  LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy. , 2014, Endocrine-related cancer.

[8]  A. Motegi,et al.  The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy. , 2009, Cancer letters.

[9]  M. Jäättelä,et al.  Combating apoptosis and multidrug resistant cancers by targeting lysosomes. , 2013, Cancer letters.

[10]  M. Wyatt,et al.  Participation of DNA repair in the response to 5-fluorouracil , 2009, Cellular and Molecular Life Sciences.

[11]  K. Kang,et al.  Elevation of cysteine consumption in tamoxifen-resistant MCF-7 cells. , 2013, Biochemical pharmacology.

[12]  Jing Zhu,et al.  Apparently low reproducibility of true differential expression discoveries in microarray studies , 2008, Bioinform..

[13]  Koji Kadota,et al.  A weighted average difference method for detecting differentially expressed genes from microarray data , 2008, Algorithms for Molecular Biology.

[14]  Rongling Wu,et al.  Differential Gene Expression in Tamoxifen-Resistant Breast Cancer Cells Revealed by a New Analytical Model of RNA-Seq Data , 2012, PloS one.

[15]  Soumya Krishnamurthy,et al.  Cellular Responses to Cisplatin-Induced DNA Damage , 2010, Journal of nucleic acids.

[16]  Rainer Breitling,et al.  Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments , 2004, FEBS letters.

[17]  Catalin C. Barbacioru,et al.  The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies , 2008, BMC Bioinformatics.

[18]  Jing Zhu,et al.  Gaining confidence in biological interpretation of the microarray data: the functional consistence of the significant GO categories , 2008, Bioinform..

[19]  J. Hayles,et al.  Ubiquitin-proteasome genes as targets for modulation of cisplatin sensitivity in fission yeast , 2011, BMC Genomics.

[20]  Xing Qiu,et al.  The effects of normalization on the correlation structure of microarray data , 2005, BMC Bioinformatics.

[21]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[22]  Andreas Rytz,et al.  The limit fold change model: A practical approach for selecting differentially expressed genes from microarray data , 2002, BMC Bioinformatics.

[23]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[24]  P. Hsieh,et al.  The mismatch repair‐mediated cell cycle checkpoint response to fluorodeoxyuridine , 2008, Journal of cellular biochemistry.

[25]  A. Naccarati,et al.  Variations in mismatch repair genes and colorectal cancer risk and clinical outcome. , 2014, Mutagenesis.

[26]  R. Kolodner,et al.  Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[28]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[29]  Johan Hansson,et al.  Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling* , 2003, The Journal of Biological Chemistry.

[30]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[31]  Jianjun Hu,et al.  Density based pruning for identification of differentially expressed genes from microarray data , 2010, BMC Genomics.

[32]  M. Dolan,et al.  Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.

[33]  Martin H. Schaefer,et al.  Protein Conservation and Variation Suggest Mechanisms of Cell Type-Specific Modulation of Signaling Pathways , 2014, PLoS Comput. Biol..

[34]  Lang He,et al.  Revealing weak differential gene expressions and their reproducible functions associated with breast cancer metastasis , 2012, Comput. Biol. Chem..

[35]  S. Howell,et al.  DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance , 2006, Molecular Cancer Therapeutics.

[36]  C. Caldas,et al.  Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. , 2006, Cancer research.

[37]  Shih-Chieh Lin,et al.  Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. , 2011, The American journal of pathology.

[38]  Evelien Vaes,et al.  Statistical analysis of differential gene expression relative to a fold change threshold on NanoString data of mouse odorant receptor genes , 2014, BMC Bioinformatics.

[39]  Naveid A Ali,et al.  Global characterization of signalling networks associated with tamoxifen resistance in breast cancer , 2013, The FEBS journal.

[40]  Maqc Consortium The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements , 2006, Nature Biotechnology.

[41]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Sergio Contrino,et al.  ArrayExpress—a public repository for microarray gene expression data at the EBI , 2004, Nucleic Acids Res..

[43]  Tom C. T. Yin,et al.  A Flexible Renewal Process Simulator for Neural Spike Trains , 1976, IEEE Transactions on Biomedical Engineering.

[44]  M. Meyers,et al.  DNA Mismatch Repair-dependent Response to Fluoropyrimidine-generated Damage* , 2005, Journal of Biological Chemistry.

[45]  Hui Xiao,et al.  Evaluating reproducibility of differential expression discoveries in microarray studies by considering correlated molecular changes , 2009, Bioinform..

[46]  Jean-Pierre Gillet,et al.  The clinical relevance of cancer cell lines. , 2013, Journal of the National Cancer Institute.

[47]  B. Pfeifer,et al.  Simultaneous production and partitioning of heterologous polyketide and isoprenoid natural products in an Escherichia coli two-phase bioprocess , 2011, Journal of Industrial Microbiology & Biotechnology.

[48]  Yue Wu,et al.  Chemotherapeutic sensitization by endoplasmic reticulum stress: Increasing the efficacy of taxane against prostate cancer , 2009, Cancer biology & therapy.

[49]  B. Stordal,et al.  Understanding cisplatin resistance using cellular models , 2007, IUBMB life.

[50]  B. Henderson,et al.  Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy , 2014, Oncotarget.

[51]  M. Tan,et al.  Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.

[52]  Pierre Baldi,et al.  A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes , 2001, Bioinform..

[53]  A K Bahn,et al.  Application of binomial distribution to medicine: comparison of one sample proportion to an expected proportion (for small samples). Evaluation of a new treatment. Evaluation of a risk factor. , 1969, Journal of the American Medical Women's Association.

[54]  J. Claverie Computational methods for the identification of differential and coordinated gene expression. , 1999, Human molecular genetics.

[55]  Mylène Brunelle,et al.  LRH-1 governs vital transcriptional programs in endocrine-sensitive and -resistant breast cancer cells. , 2014, Cancer research.

[56]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[57]  R. Riggins,et al.  Pathways to tamoxifen resistance. , 2007, Cancer letters.

[58]  Peigen Xiao,et al.  The First Insight into the Tissue Specific Taxus Transcriptome via Illumina Second Generation Sequencing , 2011, PloS one.

[59]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[60]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[61]  Werner Van Belle,et al.  Intensity Dependent Confidence Intervals on Microarray Measurements of Differentially Expressed Genes: A Case Study of the Effect of MK5, FKRP and TAF4 on the Transcriptome , 2007, Gene regulation and systems biology.